Kevin Panaro
Hematology — Dana-Farber Cancer Institute, United States
Kevin Panaro
LeadR Profile
Hematology
Subspecialties: Biochemistry - Oncology - Immunology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2023 - 2026
Number : 7
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Teclistamab versus lenalidomide-dexamethasone in high-risk smoldering multiple myeloma: a randomized phase 2 trial. molecular biology, dexamethasone, multiple myeloma, lenalidomide, therapeutics, smoldering multiple myeloma | Nat Med Top journal | 2026 | 0 |
| Randomized, Placebo-Controlled Trial of B-Cell Depletion for Prevention of Corticosteroid-Requiring Chronic Graft-Versus-Host Disease. cells, antibody formation, incidence, antibodies, adrenal cortex hormones, graft vs host disease, transplants, medical oncology, steroids, b-lymphocytes, allografts, transplantation, bronchiolitis obliterans syndrome | J Clin Oncol Top journal | 2026 | 0 |
| Ciltacabtagene autoleucel in high-risk smoldering multiple myeloma: the CAR-PRISM phase 2 trial. cells, molecular biology, multiple myeloma, therapeutics, smoldering multiple myeloma, car-t cell | Nat Med Top journal | 2026 | 0 |
| Allogeneic transplant outcomes in T-cell prolymphocytic leukemia: a single-center retrospective study. cells, incidence, lymphoma, retrospective studies, leukemia, recycling, leukemia, prolymphocytic, t-cell, transplants, t-lymphocytes, leukemia, prolymphocytic, allografts | Leuk Lymphoma | 2026 | 0 |
| Venetoclax/FluBu2 RIC transplant followed by all-oral venetoclax/decitabine maintenance for poor risk MDS/AML. decitabine, maintenance, transplants, hematologic diseases | Blood Adv | 2025 | 0 |
LeadR Networks
Main global connection map